<DOC>
	<DOCNO>NCT01351636</DOCNO>
	<brief_summary>The purpose study ascertain whether Arotinolol Hydrochloride reduce mortality cardiovascular event chronic kidney disease stage 5 patient hypertension .</brief_summary>
	<brief_title>Effect Arotinolol Hydrochloride Cardiovascular Events Hypertensive Haemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Arotinolol</mesh_term>
	<criteria>Aged 1875 yearsold ; Chronic kidney disease stage 5 haemodialysis treatment 2 month ; Patients blood pressureâ‰¥140/90 mmHg receive 2 3 antihypertensive medication 2 week ; Patients receive alfa beta blocker wash 2 week ; Written inform consent Unstable angina , myocardial infarction , symptomatic continuous arrhythmia , cardiosurgery last 2 month ; Patients take class I antiarrhythmic drug ; Resting heart rate le 60 ; Patients systolic pressure le 90 mmHg ; Patients chronic obstructive pulmonary disease asthma ; Patients cerebral infarction last 2 week ; Severe disorder liver function ; Allergy arotinolol ; Patients plan kidney transplantation near future ; Pregnancy breastfeeding ; Malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>chronic kidney disease</keyword>
	<keyword>hypertension</keyword>
</DOC>